Effects of escitalopram on stress-related relapses in women with multiple sclerosis: An open-label,randomized, controlled,one-year follow-up study |
| |
| Affiliation: | 1. First Department of Psychiatry, Athens University Medical School, Eginition Hospital, 7, Metamorfoseos str., GR-15234 Halandri-Athens, Greece;2. Department of Neurology, Athens University Medical School, Eginition Hospital, Athens, Greece;3. Department of Business Administration, University of Patras, Patras, Greece;4. Dromokaition Psychiatric Hospital, Athens, Greece;1. The Pill Box Pharmacy, Decatur, AL;2. McWhorter School of Pharmacy, Samford University, Birmingham, AL;3. Ida V. Moffett School of Nursing, Samford University, Birmingham, AL;4. Department of Nurse Anesthesia, Ida V. Moffett School of Nursing, Samford University, Birmingham, AL;1. School of Pharmacy and Medical Sciences, Sansom Institute, University of South Australia, Australia;2. Early Origins of Adult Health Research Group, School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Australia;3. FOOD plus Research Centre, School of Agriculture, Food and Wine, The University of Adelaide, Australia;4. School of Pharmacy, Menzies Health Institute Queensland, Griffith University, Australia;1. Department of Physiopathology, Institute of Rural Health, Lublin, Poland;2. Department of Pathophysiology, Medical University of Lublin, Lublin, Poland;1. Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China;2. Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China;3. Department of Pharmacy, General Hospital of Guangzhou Military Command of PLA, China |
| |
| Abstract: | A growing body of evidence supports the association between Stressful Life Events (SLEs) and increased risk for relapse in Multiple Sclerosis (MS). In this open-label, randomized, controlled, one-year prospective study we investigated the effects of escitalopram on stress-related relapses in 48 women with relapsing–remitting MS. Patients were randomly assigned either to receive escitalopram 10 mg/day (e-group, N = 24) or to continue with treatment as usual, as a control group (c-group, N = 24). SLEs were documented weekly in self-report diaries and were classified afterwards as short- or long-term depending on their psychological impact as this was subjectively felt by the patient. The cumulative risk for relapse was 2.9 times higher for controls than for escitalopram-treated patients (95% CI = 1.7–5.1, p < 0.001) and it was influenced only by long-term SLEs. In the e-group only 3 or more long-term SLEs were associated with a significant increase of the risk of a relapse during the following 4 weeks, and this risk was 4 times lower compared to the c-group. Our study shows preliminary evidence that escitalopram may constitute an effective and well-tolerated treatment option for the prevention of stress-related relapses in women with MS. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
